# Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study

> **NCT06021366** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2089 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06021366
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-07
- **Primary completion:** 2022-08-29
- **Final completion:** 2022-08-29
- **Target enrollment:** 2089 (ACTUAL)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06021366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06021366, "Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06021366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*